The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man

Thrombosis Research

Volumn 86, Issue 4, 1997, Pages 343-348

  Holst, Jan ^a,b   Lindblad, Bengt ^a   Bergqvist, David ^a,c   Hedner, Ulla ^d   Nordfang, Ole ^d   Østergaard, Per ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d NOVO NORDISK A S   (Denmark)

Author keywords

LMWH; Protamine; TFPI; UH

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

AGE FACTORS; BODY WEIGHT; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LINEAR MODELS; LIPOPROTEINS; MALE; PROTAMINES; SMOKING;

EID: 0030762592     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00078-9     Document Type: Article

References (17)

1. Petersen L.C., Valentin S., Hedner U. Regulation of the extrinsic pathway in health and disease: The role of factor VIIa and tissue factor pathway inhibitor. Thromb Res. 79:1995;1-47.
2. Sandset, P.M., Abildgaard, U., Larsen, M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50, 803-13, 1988.
3. Leizorovicz A., Picolet H., Peyrieux K.et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg. 78:1991;412-416.
4. Hull R.D., Raskob G.E., Pineo G.F.et al. Subcutaneous low-molecular-weight-heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 326:1992;975-982.
5. Holst J., Lindblad B., Bergqvist D., Garre K., Nielsen H., Hedner U., Østergaard P.B. Protamine neutralization of intravenous and subcutaneous LMWH (tinzaparin, Logiparin®). An experimental investigation in healthy volunteers. Blood Coag Fibrinol. 5:1994;795-803.
6. Lindahl, A.K., Abildgaard, U., Larsen, M.L., Aamodt, L.-M., Nordfang, O., Beck, T.C. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res suppl XIV, 39-48, 1991.
7. Lindahl, A.K., Abildgaard, U., Staalsen, R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 64, 155-68, 1991.
8. Sandset P.M., Abildgaard U., Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 47:1987;389-400.
9. Pedersen, A.H., Nordfang, O., Norris, F., Wiberg, F.C., Christensen, M., Moeller, K.B., Meidahl-Pedersen, J., Beck, T.C., Norris, K., Hedner, U., Kiesel, W. Recombinant human extrinsic pathway inhibitor, production, isolation and charachtarization of its inhibitory activity on tissue factor initiated coagulation reactions. J Biol Chem 265, 16789-93, 1990.
10. Yin, E.T. A new single stage measurement of heparin by anti-factor Xa. Semin Thromb Haemostas 11, 243-4, 1985.
11. Kristensen H.I., Østergaard P.B., Nordfang O., Abildgaard U., Lindahl A.-K. Effect of tissue factor pathway inhibitor in the Heptest® and in an amidolytic anti factor Xa assay for LMW heparin. Thromb Haemostas. 68:1992;310-314.
12. Østergaard, P.B., Beck, T.C., Ørsted, H., Larsen, A., Nordfang, O., Sandset, P.M., Hansen. J.-B. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. In preparation.
13. Brindley C.J., Taylor T., Diness V., Østergaard P.B., Chaussaud L.F. Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (Logiparin), a low molecular weight heparin, in dogs. Xenobiotica. 23:1993;575-588.
14. Harenberg, J., Siegle, M., Dempfle, C.-E., Stehle, G., Heene, D.L. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemostas 70, 942-5, 1993.
15. Bregengaard C., Nordfang O., Østergaard P., Petersen J.G.L., Meyn G., Diness V., Svendsen O., Hedner U. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemostas. 70:1993;454-457.
16. Karlsson K., Marklund S.L. Heparin-, dextran sulfate- and protamine-induced release of extracellular-superoxide dismutase to plasma in pigs. Biochem Biophys Acta. 967:1988;110-114.
17. Lupu C., Lupu F., Denneby U., Kakkar V.V., Scully M.F. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 15:1995;2055-2062.